



Annexure 6 – Additional tables and figures

1. The proportion of secondary level facilities where a social worker accompanies the referred patient (%)




Fig. 33



2. Availability of childhood cancer treatment-related departments by the type of hospital

Table 16

S. No.	Department	Public (n = 77)						Private (n = 35)								NGOs/Charitable (n = 25)							
		Medical college hospital		Super speciality (oncology)		Multispecialty with dedicated oncology unit		Medical college hospital		Super speciality (oncology)		Multispecialty with dedicated oncology unit		Multispecialty without a dedicated general oncology unit		Medical college hospital		Super speciality (oncology)		Multispecialty with dedicated oncology unit		Multispecialty without a dedicated general oncology unit	
		53		12		12		11		8		14		2		6		12		5		2	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
1	Pediatric oncology	17	32.1	10	83.3	5	41.7	5	45.5	4	50	8	57.1	0	0	2	33.3	11	91.7	3	60.0	0	0
2	Medical oncology	18	34.0	9	75.0	8	66.7	7	63.6	7	87.5	8	57.1	0	0	3	50.0	10	83.3	2	40.0	0	0
3	Radiation oncology	34	64.2	11	91.7	7	58.3	7	63.6	7	87.5	10	71.4	0	0	4	66.7	11	91.7	2	40.0	0	0
4	Surgical oncology	23	43.4	11	91.7	7	58.3	8	72.7	6	75	10	71.4	0	0	4	66.7	10	83.3	3	60.0	0	0
5	Pediatric medicine	48	90.6	3	25.0	9	75.0	10	90.9	2	25	10	71.4	2	100	6	100	5	41.7	4	80.0	1	50
6	Medicine	35	66.0	3	25.0	9	75.0	9	81.8	3	37.5	7	50.0	1	50	4	66.7	3	25.0	2	40.0	2	100
7	Haematology	20	37.7	5	41.7	8	66.7	6	54.5	5	62.5	9	64.3	0	0	3	50.0	8	66.7	2	40.0	0	0
8	Pediatric surgery	37	69.8	2	16.7	9	75.0	8	72.7	2	25	9	64.3	1	50	4	66.7	5	41.7	2	40.0	0	0
9	Surgery	39	73.6	6	50.0	10	83.3	9	81.8	2	25	7	50.0	1	50	5	83.3	3	25.0	2	40.0	1	50
10	Ophthalmology	47	88.7	3	25.0	8	66.7	11	100.0	0	0	10	71.4	0	0	4	66.7	1	8.3	2	40.0	2	100
11	Musculoskeletal oncologist	3	5.7	3	25.0	1	8.3	2	18.2	1	12.5	4	28.6	0	0	1	16.7	5	41.7	3	60.0	0	0
12	Orthopaedics	48	90.6	3	25.0	10	83.3	10	90.9	1	12.5	11	78.6	1	50	5	83.3	3	25.0	3	60.0	1	50
13	Neurosurgery	36	67.9	3	25.0	8	66.7	9	81.8	2	25	12	85.7	0	0	4	66.7	5	41.7	1	20.0	0	0
14	Radiology	44	83.0	11	91.7	11	91.7	10	90.9	6	75	13	92.9	2	100	6	100	12	100	4	80.0	0	0
15	Nuclear medicine	15	28.3	7	58.3	5	41.7	4	36.4	5	62.5	9	64.3	0	0	1	16.7	10	83.3	0	0.0	0	0
16	Pathology	48	90.6	12	100.0	11	91.7	10	90.9	6	75	13	92.9	2	100	6	100	12	100	4	80.0	2	100
17	Palliative medicine	21	39.6	11	91.7	5	41.7	4	36.4	6	75	9	64.3	1	50	3	50.0	10	83.3	4	80.0	1	50



3. Availability of departments for childhood cancer treatment at secondary hospitals

Table 17

Department	Public n = 21						Private n = 13						NGO/charitable n = 02					
	Available and treating	%	Available but not treating	%	Not available	%	Available and treating	%	Available but not treating	%	Not available	%	Available and treating	%	Available but not treating	%	Not available	%
Paediatrics	15	71.4	4	19.0	2	9.5	11	84.6	2	15.4	-	-	2	100	-	-	-	-
Medical oncology	4	19.0	9	42.9	8	38.1	8	61.5	3	23.1	2	15.4	1	50	1	50	-	-
Radiation oncology	7	33.3	6	28.6	8	38.1	7	53.8	2	15.4	4	30.8	-	-	2	100	-	-
Surgical oncology	1	4.8	11	52.4	9	42.9	7	53.8	4	30.8	2	15.4	-	-	2	100	-	-
Medicine	15	71.4	6	28.6	-	-	10	76.9	2	15.4	1	7.7	-	-	2	100	-	-
Haematology	3	14.3	8	38.1	10	47.6	4	30.8	5	38.5	4	30.8	2	100	-	-	-	-
Paediatric surgery	6	28.6	7	33.3	8	38.1	5	38.5	6	46.2	2	15.4	1	50	1	50	-	-
Surgery	14	66.7	7	33.3	-	-	11	84.6	1	7.7	1	7.7	-	-	2	100	-	-
Orthopaedics	14	66.7	6	28.6	1	4.8	9	69.2	3	23.1	1	7.7	-	-	2	100	-	-
Neurosurgery	2	9.5	10	47.6	9	42.9	8	61.5	3	23.1	2	15.4	2	100	-	-	-	-
Radiology	13	61.9	8	38.1	0	0.0	11	84.6	1	7.7	1	7.7	2	100	-	-	-	-
Nuclear medicine	-	-	11	52.4	10	47.6	2	15.4	8	61.5	3	23.1	-	-	2	100	-	-
Pathology	16	76.2	5	23.8	-	-	10	76.9	2	15.4	1	7.7	2	100	-	-	-	-
Palliative medicine	14	66.7	3	14.3	4	19.0	5	38.5	4	30.8	4	30.8	-	-	2	100	-	-
Ophthalmolog y	13	61.9	6	28.6	2	9.5	6	46.2	4	30.8	3	23.1	1	50	1	50	-	-



4. Waiting time for an appointment at different departments in tertiary hospitals




Fig. 34




Fig. 35



5. Availability of referral for support facilities that were not available and mode of referral at tertiary hospitals




Fig. 36




Fig. 37




Fig. 38



6. Average waiting time to avail of an appointment at the treating departments in secondary level hospitals




Fig. 39




Fig. 40




Fig. 41



7. Average waiting time for getting an appointment for laboratory services at tertiary hospitals

Table 18: Average waiting time for lab services at public tertiary hospitals

Investigation	Same day		Within one week		Within 2 weeks		Beyond 2 weeks	
	n	%	n	%	n	%	n	%
Histopathology	20	27.3	40	54.7	12	16.4	1	6.0
Immunohistochemistry	12	26.6	24	53.3	8	17.7	1	5.6
Flowcytometric Immunophenotyping	8	30.7	15	57.6	3	11.5		0
Cytogenetics	-	-	-	-	3	20	8	40
Tumour markers	15	31.2	24	50	7	14.5	2	13.7
Fluorescence in situ hybridization (FISH)	2	13.3	9	60	2	13.3	2	15
RT-PCR testing	18	40	21	46.6	5	11.1	1	9
HLA typing	2	16.6	6	50	2	16.6	2	12
Therapeutic drug monitoring	8	38.0	12	57.1	1	4.7		0

**Table 19: Average waiting time for lab services at Private tertiary hospitals**

Investigation	Same day		Within one week		Within two weeks		Beyond 2 weeks	
	n	%	n	%	n	%	n	%
Histopathology	16	50.0	14	43.7	2	6.2	-	-
Immunohistochemistry	11	44.0	11	44.0	2	8.0	1	4.0
Flowcytometric Immunophenotyping	13	61.9	8	38.0	-	-	-	0
Cytogenetics	-	-	-	-	-	-	1	8.3
Tumour markers	18	62.0	10	34.4	1	3.4	-	-
Fluorescence in situ hybridization (FISH)	3	30.0	7	70.0	-	-	-	-
RT-PCR testing	11	61.1	7	38.8	-	-	-	-
HLA typing	3	37.5	3	37.5	2	25.0	-	-
Therapeutic drug monitoring	8	72.7	3	27.2	-	-	-	-

**Table 20: Average waiting time for lab services at NGO/charitable tertiary hospitals**

Investigation	Same day		Within one week		Within 2 weeks		Beyond 2 weeks	
	n	%	n	%	n	%	n	%
Histopathology	10	47.6	10	47.6	1	4.7	0	0
Immunohistochemistry	8	47.0	6	35.2	3	17.6	0	0
Flowcytometric Immunophenotyping	6	60	4	40	0	0		0
Cytogenetics	0	0	2	25	0	0	2	25
Tumour markers	13	68.4	5	26.3	1	5.2	0	0
Fluorescence in situ hybridization (FISH)	3	42.8	3	42.8	1	14.2	0	0
RT-PCR testing	10	71.4	3	21.4	1	7.1	0	0
HLA typing	2	40	1	20	2	40	0	0
Therapeutic drug monitoring	5	62.5	2	25	1	12.5		0



8. Availability and referral services for laboratory services were not available at the tertiary hospitals

Table 21: Availability and mode of referral services for laboratory services that are not available at the public tertiary hospital

Investigation	Patients' referral when the investigation is unavailable at the tertiary public hospital								
		Pvt lab		Govt hospital		Other		Not referred	
	N	n	%	n	%	n	%	n	%
Histopathology	4	1	25	2	50.0	1	25.0	0	0
Immunohistochemistry	32	15	46.8	9	28.1	3	9.3	4	12.5
Flowcytometric Immunophenotyping	51	22	43.1	18	35.2	2	3.9	9	17.6
Cytogenetics	62	30	48.3	21	33.8	3	4.8	4	6.4
Tumour markers	29	12	41.3	11	37.9	1	3.4	5	17.2
HLA typing	65	31	47.6	21	32.3	3	4.6	10	15.3
Therapeutic drug monitoring	56	23	41.0	14	25.0	4	7.1	15	26.7

**Table 22: Availability and mode of referral services for laboratory services that are not available at the private tertiary hospital**

Investigation	Patients' referral when the investigation is unavailable at the tertiary Private hospital								
	N	Pvt lab		Govt hospital		other		Not referred	
		n	%	n	%	n	%	n	%
Histopathology	3	2	66.6	1	33.3	0	0		0
Immunohistochemistry	10	6	60.0	3	30	1	10	0	0
Flowcytometric Immunophenotyping	14	9	64.2	3	21.4	1	7.1	1	7.1
Cytogenetics	23	20	86.9	2	8.6	0	0	1	4.3
Tumour markers	6	5	83.3	1	16.6		0		0
HLA typing	27	22	81.4	4	14.8	0	0	1	3.7
Therapeutic drug monitoring	24	12	50	4	16.6	1	4.1	6	25

Table 23: Availability and mode of referral services for laboratory services that are not available at NGO/Charitable hospital

Investigation	Patients' referral when the investigation is unavailable at the tertiary NGO/Charitable hospital								
	N	Pvt lab		Govt hospital		Other		Not referred	
		n	%	n	%	n	%	n	%
Histopathology	4	3	75	0	0	1	25	0	0
Immunohistochemistry	8	5	62.5	1	12.5	1	12.5	0	0
Flowcytometric Immunophenotyping	15	11	73.3	2	13.3	1	6.6	1	6.6
Cytogenetics	17	13	76.4	2	11.7	0	0	2	11.7
Tumour markers	6	4	66.6	1	16.6	0	0	0	0
HLA typing	20	15	75	2	10	0	0	3	15
Therapeutic drug monitoring	17	10	58.8	3	17.6	0	0	4	23.5



9. Average waiting time for radiologic and nuclear medicine services at tertiary hospitals




Fig. 42

10. Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital




Fig. 43



11. Average waiting time for diagnostic services at secondary level hospitals




Fig. 44




Fig. 45




Fig. 46

12. Average waiting time to avail of specified treatment procedures at tertiary hospitals




Fig. 47




Fig. 48




Fig. 49



13.Means for seeking consultation from specialists not available in the tertiary hospital




Fig. 50




Figure 51



14. Drugs for palliative care

14.1 Availability and costing of drugs used in palliative care in public tertiary hospitals




Fig. 52




Fig. 53



14.2 Availability and costing of drugs used for palliative care at private tertiary hospitals




Fig. 54




Fig. 55



14.3 Availability and costing of drugs used in palliative care in NGO/charitable tertiary hospitals




Fig. 56




Fig. 57



15.Targeted therapies




Fig. 58




Fig. 59



16. Anti-neoplastic drugs

16.1 Availability and costing of antineoplastic drugs at public tertiary hospitals




Fig. 60




Fig. 61



16.2 Availability of antineoplastic drugs at private tertiary hospitals




Fig. 62




Fig. 63



16.3 Availability and costing of antineoplastic drugs at NGO/charitable tertiary hospitals




Fig. 64




Fig. 65



17. Reasons for treatment denial and treatment abandonment




Fig. 66




Fig. 67




Fig. 68




Fig. 69



Table 24: Delivery of childhood cancer care services at tertiary hospitals impacted by COVID pandemic

S. No.	Delivery of childhood cancer care services	Public (n = 77)		Private (n = 35)		NGO/ charitable (n = 25)	
		n	%	n	%	n	%
Impact of COVID 19 pandemic on the delivery of childhood cancer care services at the hospital		44	57.1	18	51.4	13	52.0
1.	Complete closure of paediatric cancer care services	3	6.8	0	0	1	7.6
2.	Ceased evaluating new cases of suspected cancers	14	31.8	3	16.6	3	23.0
3.	Decrease in new paediatric cancer diagnoses	31	70.4	11	61.1	10	76.9
4.	Increase in treatment abandonment	32	72.7	9	50.0	9	69.2
5.	Reduced surgical care	20	45.4	8	44.4	4	30.7
6.	Modifications in chemotherapy regimens	25	56.8	8	44.4	9	69.2
7.	Interruptions in radiotherapy	21	47.7	9	50.0	5	38.4
8.	Unavailability of chemotherapy agents	17	38.6	6	33.3	3	23.0
9.	Shortage of blood products	21	47.7	9	50.0	9	69.2
10.	Telemedicine use	21	47.7	4	22.2	6	46.1